Prognostic value of the “dynamic” R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2024-08-03 DOI:10.1002/hon.3302

Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida

{"title":"Prognostic value of the “dynamic” R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies","authors":"Taku Kikuchi, Yuki Oda, Ukyo Kondo, Nobuhiro Tsukada, Kodai Kunisada, Chiaki Matsumoto, Moe Nomura-Yogo, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida","doi":"10.1002/hon.3302","DOIUrl":null,"url":null,"abstract":"<p>To retrospectively analyze whether the second revision of the international staging system (R2-ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti-CD38 antibody-based triplet treatments. High-risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive if detected once. R2-ISS was recalculated at the initiation of treatment and defined as “dynamic R2-ISS.\" Data from 150 patients who underwent the defined treatments were analyzed. The median progression-free survival (PFS) was 19.5 months, and the median overall survival (OS) was 36.5 months. Dynamic R2-ISS significantly stratified prognoses for both PFS and OS. The median PFS for patients with dynamic R2-ISS IV was 3.3 months, and the median OS was 11.7 months, indicating extremely poor outcomes. Although the Revised International Staging System (R-ISS) calculated at the initiation of treatment significantly stratified treatment outcomes, the patients classified as R-ISS could be further stratified by R2-ISS to provide better prognostic information. Dynamic R2-ISS showed potential as a prognostic tool in patients with MM who are treated with anti-CD38 antibody-based triplet therapies.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 5","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3302","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To retrospectively analyze whether the second revision of the international staging system (R2-ISS) influenced prognosis at treatment initiation in patients with multiple myeloma (MM) receiving anti-CD38 antibody-based triplet treatments. High-risk chromosomal abnormalities were examined from diagnosis to treatment initiation and considered positive if detected once. R2-ISS was recalculated at the initiation of treatment and defined as “dynamic R2-ISS." Data from 150 patients who underwent the defined treatments were analyzed. The median progression-free survival (PFS) was 19.5 months, and the median overall survival (OS) was 36.5 months. Dynamic R2-ISS significantly stratified prognoses for both PFS and OS. The median PFS for patients with dynamic R2-ISS IV was 3.3 months, and the median OS was 11.7 months, indicating extremely poor outcomes. Although the Revised International Staging System (R-ISS) calculated at the initiation of treatment significantly stratified treatment outcomes, the patients classified as R-ISS could be further stratified by R2-ISS to provide better prognostic information. Dynamic R2-ISS showed potential as a prognostic tool in patients with MM who are treated with anti-CD38 antibody-based triplet therapies.

查看原文本刊更多论文

在接受抗 CD38 抗体三联疗法的多发性骨髓瘤患者中，"动态 "R2-ISS 的预后价值。

目的：回顾性分析国际分期系统第二次修订版（R2-ISS）是否会影响接受抗CD38抗体三联疗法的多发性骨髓瘤（MM）患者开始治疗时的预后。从诊断到开始治疗的整个过程中都对高危染色体异常进行了检查，如果检测到一次，则认为是阳性。在开始治疗时重新计算 R2-ISS，并将其定义为 "动态 R2-ISS"。对 150 例接受了定义治疗的患者的数据进行了分析。中位无进展生存期（PFS）为19.5个月，中位总生存期（OS）为36.5个月。动态R2-ISS对PFS和OS的预后有明显的分层作用。动态R2-ISS IV患者的中位PFS为3.3个月，中位OS为11.7个月，预后极差。虽然在开始治疗时计算的修订版国际分期系统（R-ISS）能显著地对治疗结果进行分层，但被归类为R-ISS的患者可以通过R2-ISS进一步分层，以提供更好的预后信息。对于接受抗CD38抗体三联疗法治疗的MM患者，动态R2-ISS显示出作为预后工具的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.